HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

NCT06554184 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

706

Enrollment

INDUSTRY

Sponsor class

Conditions

Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Interventions

DRUG: HR20013 + dexamethasone + palonosetron placebo
DRUG: Palonosetron + dexamethasone + HR20013 placebo

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.